Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, those 15k shares sold in the last hour on Friday were really what did it...
Did you not see? He and some Yahoo posters accused PRED of violations. Lol...
BTW, I also accuse Microsoft of SEC violations... everyone start shorting.
But in seriousness, assume they are referring to the Tim Lacy non-8k... but missing the fact that the company wasn't SEC reporting at the time of dismissal and therefore not requiring an 8-k. Was also noted in the 10-12G.... no violations, just preying on ignorance.
Seems like too much of a deviation from their current IP/platform.
Refreshing to have you over here. Thanks, Thomas. Great posts.
Thomas is Thomas DeShazo of Avira Financial among other things (Molecular Defenses, LDJ Capital, Avira Sciences, etc). All the credibility to back it up and the lawsuit.
Thanks for reposting. Would you also be able to elaborate on Avira Financial and what consulting services is provided for companies? Have been curious for a while on the agreement with PRED, but assume privacy/non-disclosure on specifics... so on a general basis.
Yep... welcome to the land of the pinks. The only place you can either make 100x or lose it all within a few months. There's a reason why many institutional are barred from trading on this exchange and why many retail traders avoid.... but you'll never find a risk/reward like it elsewhere.
That's why we have to keep pointing to the story from the company, it's why most of us invested, and so long as it's unchanging most of us are ignoring the price until the big boards. Regardless of what many hindsight-experts say, it's near impossible to predict any of the movements for the very manipulation reasons stated (unless trading manipulation is your sole strategy).
Company isn't catering to the retail investor at this stage. Most biotechs on the big boards are primarily institutional holdings as well (Pfizer runs around 75%). If investment funds and banks want to get involved, they are more at an advantage to keep news held back and price down until they can jump in at volume.
They're doing things the right way, just give it time.
We're all going to look back at this time and wish we bought more. Relax...
I see a Hindenburg Twitter post incoming...
Tough to say, volume per price still in peanuts range.
Regarding Tim Lacy, let's see if I have this correct:
1. Tim Lacy left the company early this year.
- His LinkedIn states an end date of employment in February 2019.
- Form 3 filed for him on Feb. 26th or 2019
2. He was an officer, as per noted in the form 3 filing.
3. Tim's departure was prior to SEC reporting effectiveness, meaning an 8-K would not be required.
4. The company in the latest effective filings did not note him as an officer nor director, and even noted him as a former employee:
To clarify, the video you're referencing was from midday yesterday and he referenced someone bought 200k in the open and suspected 500k at the close. It was accidentally posted this morning as well.
Coming back to this topic...
Avira Sciences (see Avira Financial - subsidiary - text below) as of latest linkedin also now shows Allan Weinstein working with them (past history includes 20yrs as a VP of Eli Lilly). The Eastwood lawsuit was also dismissed by the judge earlier this year.
Will be watching to see if there is anything tied to PRED... something big has to justify the 5M+ shares given. Still not sure of Avira's consulting agreement, but nice to know that there are serious names tied to this and no black marks.
10-12G text on Avira Financial consulting agreement:
Who's the President of ASRM again? Our boy Hugh Taylor (Scientific Advisory Board).
https://news.yale.edu/2018/10/10/taylor-elected-2021-president-american-society-reproductive-medicine
But no, definitely a sham.
This is important....
Keep an eye on Sure Genomics (http://www.suregenomics.com). Ken Ward is also on the scientific advisory board here with some other big names. Lot of media attention in 2016... then a massive silence. Pure speculation, but would not be surprised to see this become under the PREDbrella.
Generic letter sent to all, see confirmation: https://www.fda.gov/media/119936/download
IQVIA partnership was PRED's response... the correct one.
Inaction and silence may be frustrating now, but long-term I believe will be at our benefit. The company clearly, as evidenced from the past few years, does not cater to the general OTC/Pink investor. This board is a means to an end only, and the only reason we appear to have any information is because they are doing the bare minimum to satisfy the Nasdaq/SEC requirements.
You're right, none of us know anything... except for who is managing and leading this company, and the connections we have so far seen such as Thermo and what else we can squeeze from sites such as linkedin. The speculation and rumors, while unsubstantiated, do hold very real potentials and likelihoods. The more I spend digging into who we have, the more confident I am that what we have here can live up to all of it.
Most starting companies are built initially on potential alone. Look at Tesla for instance, they have been pissing away money forever, but have been as valued as high as Ford with very little to justify. PRED for me, the risk/reward is based upon the potential, and I have never seen anything with as much of a worthwhile gamble.
Personally, I'm invested with an amount that I would be comfortable watching go to zero. That said, if we even see a tenth of what I think is possible, I'll take an early retirement.
Yes, my projections were wrong at that time, but timing has never been my strong suit. Those targets have not changed, but are currently just delayed with uplist. I've believed this stock was going to be 25B+ since I started buying, and as long as the story is the same I won't change that strategy. I wouldn't want to be the guy who sold AMZN, NOW, TSLA, etc... when they had a rocky couple bumps in the early days. We'll all look back on this time and wish we accumulated more IMO.
Not going to go through your post history and call out the many inaccuracies as well. Good luck to you, hope you do profit during this period, but not my game.
Still green and still very bullish. Never had a short-term perspective on this stock, and nothing has changed my opinion to change my strategy. Playing the day-to-day may be working right now, but that could all change in an instant.
Sit back and relax... all will be rewarded.
To quote the PRED bible:
Curse of the pinks in combination with little to no marketing, good thing that's all temporary.
Yes, will PM to coordinate in Toronto. I do owe you a steak as promised. Lol
If you compare PRED to the competitive spaces they are not overvalued. They are also appropriately weighted for their potential short-term earnings and results. A billion dollars is not a lot of money...
Also look at TSLA or any other large upcoming entity in a burgeoning space... there is a lot of value tied to just potential. Genetic diagnostic/treatment is about as big as it gets, and PRED I'm my opinion is worth $10 minimum in it's current state with no additional news.
*Most are profitable. There was a lot of volume traded (suspect much still shorted) at the 1.75-2.50 range that we currently fall in.
For those wondering outcome, response by the SEC for any raised concern is shown below. Summary is "thanks, and we can't tell you anything".
I had to clarify with the Admins. Clay is a commercial user ($95/mo subscription) and is allowed to link back to his personal board, which can in turn link back to his site.
https://investorshub.advfn.com/boards/aboutirps.aspx
If a flat earth believer asked me to disprove their beliefs/claims, I would spend no time answering. The reason is the same here. To deep dive all of the details for something so clearly errant, financially motivated, and easily contextualized in either direction… would be a waste of efforts that could be spent researching more important details of the company.
We have provided more accurate context over the past few years on this board (nothing in the report was new to me). We have discussed the credibility of BF Borgers, the acquisition of Lifecode, what role Merle actually played and what the actual outcome of his run-in with the SEC was, what the actual outcome of the Sagent v Infusive suit was, how Juneau/PRED setup share structures and formed, etc…
All I will continue to point to is the credibility and service length of all of the scientists, management, board, and partners PRED has currently announced. This is not a Theranos, and does not follow any scam business model that I have ever been aware of. If you want the actual context, and not just speculation on either side, I would recommend you wait for the long-term litigation from the individual party.
Go back through the past few days of posts, and you'll see many discussing very clear inaccuracies, contextual misses, etc.
They can always r/s. Not needed, but an option. In the end won't matter, they'll be priced appropriately very soon.
1. Theranos was a marketing wonder with very little scientific support.
PRED has no marketing currently and is very much not well known by the general public/newsbase (retail investor). They are very heavily invested in the scientific community/conferences.
2. Theranos ran a team comprised of very young individuals with little to no experience, and the Board had little to no healthcare experience.
Many of PREDs board (not including scientific advisory) have very strong technical backgrounds in the industry. PREDs employees and board also carry much more experience on average than anything we saw with Theranos.
3. Theranos' solution (single product) said everything we know about physics and chemistry fundamentals is wrong.
PREDs solution/company (multiple products) questions no fundamentals and is generally agreed to be a space with significant viability and growth.
4. Theranos had no income stream.
PRED is growing revenues month over month and requires very little, if any, financing to support R&D.
Thanks for posting, $160 is only the start over the next year!
Smart, have added normally with bonuses myself, but can't seemingly go wrong. Should be in every investor's portfolio.
Even in this community, where minor things can be over exaggerated in importance, at the time very few thought the paid promotions were going to help the stock price. Not sure why one would believe that those publications (e.g. Wolf) would have any bearing on the price of this stock long or short term.
IMO, the shorts paid for the articles to both short higher and reference in the article.
This is where language becomes very important. If they responded with your post, Hindenburg could easily respond with the same info as before/reckte saying the company is denying public facts.
The company responded in the correct manner, by not giving any ammunition to Hindenburg, making their response article look like a inexperienced whining.
Don't take their response as anything but carefully written and worded.
Not promoted by the company, which was previously clarified by the company and discussed here. If you're interested, may be worth an exercise to search this board as many of your open questions have been previously discussed at length.
As of last year February all GlobenewsWire releases have had the name removed. There may be a contract open (not aware), but they are not operating in any capacity and post PRED news on an inconsistent delay.
Byproduct of Merle IMO. Yes appears to have ties to all Merle companies during the infancy period. And if I were Yes, I would keep posting PRED too... only more credibility to pull in more clientele.
Not currently hired as the PR firm, but is still posting PRs. Not going to speculate on reasoning, but not paid.